Abstract:Introduction: Evasion of the immune system is a hallmark of cancer and understanding immune escape mechanisms has led to the development of immunotherapies to boost anti-tumor immunity. CD47 is an immunosuppressive protein that transduces a "don't eat me" signal when bound to the SIRPα receptor on antigen presenting cells (APCs). Cancer cells exploit CD47 to block phagocytosis by APCs and dampen anti-tumor immune responses. Various inhibitors of the CD47-SIRPα signaling axis, including monoclonal antibodies, have been developed as immunotherapeutic agents for administering CD47 blockade in cancer patients, and are currently being evaluated in clinical trials. Understanding mechanisms of tumor resistance to CD47-targeted immunotherapy will guide its clinical development and could inform rational combination therapies to enhance its efficacy. Since CD47 is prognostically and functionally relevant in non-small cell lung cancer (NSCLC), we investigated the response of two syngeneic, murine lung cancer models to CD47 loss-of-function (LOF). Methods: CRISPR/Cas9 was used to knockout (KO) CD47 in two murine (LLC, CMT167) syngeneic models of NSCLC. Tumor growth studies were conducted in immune competent (C57BL/6) mice orthotopically implanted with wildtype (WT) or CD47 KO cells. Immunophenotyping of tumors was done prior to humane endpoints using flow cytometry to compare immune cell infiltration in WT versus CD47 KO tumors to assess lung tumor response to CD47 LOF. Results: Survival analyses of immunocompetent hosts with orthotopic LLC and CMT tumors revealed that mice with CD47 KO tumors lived longer than those with WT tumors, although CD47 KO tumors were ultimately lethal. Tumor immunophenotyping revealed higher frequencies of MHC-IIhighCD80+ M1 macrophages and activated cytotoxic CD69+CD8+ T cells in CD47 KO tumors compared to WT. Moreover, the percentage of PD-L1+ tumor and myeloid cells was greater in CD47 KO tumors compared to WT tumors, suggesting PD-L1 may be upregulated on various cell types in the TME as a compensation mechanism when CD47 is inhibited. Conclusion: Consistent with the literature, our findings show that CD47 LOF in lung cancer cells prolongs the survival of tumor-bearing mice and promotes infiltration of anti-tumor immune cells in two orthotopic, syngeneic NSCLC models. Upregulation of PD-L1 in cancer and myeloid cells from CD47 KO tumors was also observed, revealing a putative PD-L1-driven mechanism of resistance to CD47 blockade. Although additional preclinical and clinical studies are needed to confirm the generalizability of our observations and to validate them in patients treated with CD47-targeted therapy, our findings provide evidence to support continued development of approaches for combining CD47 and PD-L1 blockade as an effective immunotherapeutic strategy for the treatment of NSCLC. Citation Format: Asa P.Y Lau, Kelsie L Thu. Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr B007.

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

EGFR Oncogenic Mutations in NSCLC Impair Macrophage Phagocytosis and Mediate Innate Immune Evasion Through Up-Regulation of CD47

Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies

Cd47-Blocking Immunotherapies Stimulate Macrophage-Mediated Destruction of Small-Cell Lung Cancer

Enhancing anticancer activity of macrophages through rational drug combinations

Targeting Cd47 and Autophagy Elicited Enhanced Antitumor Effects in Non-Small Cell Lung Cancer

Macrophage checkpoint blockade: results from initial clinical trials, binding analyses, and CD47-SIRPα structure–function

Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells

Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization

Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced suppression

Abstract A055: CD47 predominates over CD24 as a macrophage immune checkpoint in cancer

Anaplastic Lymphoma Kinase (ALK) Inhibitors Enhance Phagocytosis Induced by CD47 Blockade in Sensitive and Resistant ALK-Driven Malignancies

Engineered CD47 protects T cells for enhanced antitumour immunity

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

Targeting Microtubules Sensitizes Drug Resistant Lung Cancer Cells to Lysosomal Pathway Inhibitors.

Engineered Nanoparticles for Enhanced Antitumoral Synergy Between Macrophages and T Cells in the Tumor Microenvironment

Anlotinib Combined with Anti‐PD1 Potentiates Anti‐Tumor Immunity Via Immunogenic Cell Death and Macrophage Reprogramming

Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer

Abstract B007: Upregulation of PD-L1 as a mechanism of resistance to CD47 inhibition in non-small cell lung cancer

Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function

Dual Targeted Immunotherapy Via in Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells